Thomas Grinda

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

Thomas Grinda, Alison Antoine, William Jacot et al. · ESMO Open · 2021 · 134 citations · Full text

Medicine, Oncology, Breast Oncology +12

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Thomas Grinda, Natacha Joyon, Amélie Lusque et al. · npj Breast Cancer · 2021 · 90 citations · Full text

Medicine, Oncology, Breast Oncology +14

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Thomas Grinda, Alison Antoine, William Jacot et al. · European Journal of Cancer · 2023 · 32 citations · Full text

Medicine, Oncology, Breast Oncology +8

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife‐Hachem, Khalil Saleh, Florence Pasquier et al. · HemaSphere · 2021 · 25 citations · Full text

Medicine, Molecular Genetics, Oncology +15

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer

Paolo Tarantino, David Lee, Julia Foldi et al. · ESMO Open · 2025 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16